Background: Juvenile domestic swine have been extensively used to test safety of various antirestenotic therapies in peripheral arteries but it generally fails to provide insights into efficacy. We investigated the potential of different combinations of balloon or stent injuryϩtreatment models in familial hypercholesterolemic (FH) swine to predict the antirestenotic efficacy of drug-coated balloons. Methods: Iliofemoral arteries of 32 FH swine were subjected to (1) denudation by a Fogarty catheter immediately followed by DCB or Control (uncoated PTCA balloon) treatment (De Novo DenudationϩNo Stent), (2) balloon overstretch and stent placement immediately followed by the same DCB or Control treatment (De Novo OverstretchϩStent), or (3) balloon overstretch and stent placement followed by the same DCB or Control treatment 14-21 days later (In-Stent Restenosis). In all models, the net neointimal proliferation was evaluated 28 days post-treatment by endovascular imaging (IVUS or OCT). Results: As expected, the neointimal response was much more robust in the De Novo OverstretchϩStent than in the De Novo DenudationϩNo Stent model, but both De Novo FH swine models failed to show the difference between DCB and Control. In contrast, 2 separate studies employing the In-Stent Restenosis model on the basis of FH swine, demonstrated reduction of average stenosis by ϳ50% by DCB in comparison to Control (TABLE) . Conclusions: The peripheral in-stent restenosis model, in which neointimal proliferation was induced by stent placement in iliofemoral arteries of FH swine and dilated 2-3 weeks later by DCB or Control uncoated balloon, reliably differentiated the antirestenotic effect of DCB from the Control effect in peripheral arteries. In contrast, either De Novo model (of contemporaneous injuryϩtreatment) developed in FH swine was not successful in that regard. 
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